Westover Capital Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Westover Capital Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29,200	Closed	-$819K	–	179
2021 Q4	$819K	Hold	29,200	–	–	0.24%	83
2021 Q3	$993K	Hold	29,200	–	–	0.31%	76
2021 Q2	$1.19M	Hold	29,200	–	–	0.38%	65
2021 Q1	$1.18M	Hold	29,200	–	–	0.4%	63
2020 Q4	$1.73M	Sell	29,200 -7,600	-21%	-$392K	0.62%	45
2020 Q3	$1.79M	Sell	36,800 -7,200	-16%	-$303K	0.73%	43
2020 Q2	$2.13M	Sell	44,000 -9,800	-18%	-$357K	1%	34
2020 Q1	$1.5M	Buy	+53,800	New	+$1.5M	0.81%	41

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Westover Capital Advisors's ADPT Position: Q1 2022 in Review

Westover Capital Advisors sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 29,200 shares — an estimated $819K sold.

Westover Capital Advisors first reported a position in ADPT in Q1 2020 and held it in 8 quarters. The position peaked at $2.13M in Q2 2020. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Westover Capital Advisors reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
Westover Capital Advisors sold 29,200 Adaptive Biotechnologies shares in Q1 2022, an estimated $819K.
Westover Capital Advisors first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 8 quarters.
Westover Capital Advisors's Adaptive Biotechnologies position peaked at $2.13M in Q2 2020.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Westover Capital Advisors's 13F filing for Q1 2022, filed 13 May 2022.